[Form 4] LeMaitre Vascular, Inc. Insider Trading Activity

Rhea-AI Filing Summary

LeMaitre Vascular, Inc. (LMAT) insider report: George W. LeMaitre, Chairman and CEO, reported transactions on 09/03/2025 showing two non-derivative dispositions of 10,600 shares each (transaction code G), reducing his reported beneficial ownership from 1,716,403 to 1,705,803 shares following the second line item. The filing also records multiple dividend equivalent rights credited on restricted stock and performance share unit awards that convert economically to common shares; individual accruals range from 2.0944 to 10.238 and represent fractional share equivalents under vesting schedules. The form is signed and dated 09/05/2025.

Positive

• None.

Negative

• Insider dispositions: Two non-derivative dispositions of 10,600 shares each were reported on 09/03/2025, totaling 21,200 shares disposed.
• Reduction in reported beneficial ownership: Post-transaction beneficial ownership is reported as 1,705,803 shares on the second line item, down from 1,716,403 shares prior to that line.

Insights

Corporate Governance Expert

TL;DR: Insider sales were reported but holdings remain large; dividend-equivalent accruals reflect ongoing compensation vesting.

George W. LeMaitre, serving as Chairman and CEO, reported two planned dispositions of 10,600 shares each on 09/03/2025 under transaction code G, which typically indicates a sale under a Rule 10b5-1 trading plan or similar arrangement. His post-transaction beneficial ownership remains above 1.7 million shares, indicating sustained ownership alignment with shareholders. The filing separately itemizes accrued dividend equivalent rights from RSU and PSU awards, specified with precise per-unit equivalents, which simply document vesting-related economic accruals rather than new grants.

Securities Analyst

TL;DR: Reported disposals are explicit and modest relative to total holdings; no derivative exercises or option grants disclosed.

The Form 4 shows two non-derivative dispositions (each 10,600 shares) on 09/03/2025 and multiple accrual entries for dividend equivalent rights tied to prior RSU/PSU awards. There is no exercise of options or issuance of new derivative securities recorded. The aggregate reduction from the two reported disposals totals 21,200 shares, while outstanding dividend equivalent rights are recorded as fractional equivalents that will vest proportionately with the underlying awards.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LeMaitre George W

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		G		10,600	D	$0	1,716,403	D
Common Stock	09/03/2025		G		10,600	D	$0	1,705,803	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(1)	09/04/2025		A		2.0944		(1)	(1)	Common Stock	2.0944	$0	48.5172	D
Dividend Equivalent Rights	(2)	09/04/2025		A		3.0132		(2)	(2)	Common Stock	3.0132	$0	52.9773	D
Dividend Equivalent Rights	(3)	09/04/2025		A		6.1418		(3)	(3)	Common Stock	6.1418	$0	73.9603	D
Dividend Equivalent Rights	(4)	09/04/2025		A		6.1418		(4)	(4)	Common Stock	6.1418	$0	73.2516	D
Dividend Equivalent Rights	(5)	09/04/2025		A		7.8747		(5)	(5)	Common Stock	7.8747	$0	56.7551	D
Dividend Equivalent Rights	(6)	09/04/2025		A		9.4371		(6)	(6)	Common Stock	9.4371	$0	59.9811	D
Dividend Equivalent Rights	(7)	09/04/2025		A		10.238		(7)	(7)	Common Stock	10.238	$0	34.2516	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/2/2020 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

6. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

7. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Nathan Ulrich	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did George W. LeMaitre report on Form 4 for LMAT?

He reported two non-derivative dispositions of 10,600 shares each on 09/03/2025 (transaction code G).

How many LMAT shares did the filings show George W. LeMaitre owns after the reported sales?

The filing lists 1,716,403 shares after the first reported line and 1,705,803 shares following the second reported disposition.

What are the dividend equivalent rights disclosed in the Form 4?

The filing records multiple dividend equivalent rights tied to prior RSU and PSU awards with per-unit equivalents ranging from 2.0944 to 10.238, each converting economically to common stock upon vesting.

When was the Form 4 signed and submitted?

The filing is signed by Nathan Ulrich and dated 09/05/2025.

Do the transactions indicate option exercises or new derivative grants?

No option exercises or new derivative grants are reported; only non-derivative dispositions and accrued dividend equivalent rights are listed.